Literature DB >> 1646903

The correlation between the immunohistochemical expression of DF3 antigen and serum CA15-3 in breast cancer patients.

N Ohuchi1, S Sato, M Akimoto, Y Taira, N Matoba, K Takahashi, S Mori.   

Abstract

The immunohistochemical expression of DF3 antigen and serum concentrations of CA15-3, a breast carcinoma-associated antigen recognized by the monoclonal antibodies (MAbs) 115D8 and DF3, was investigated in breast cancer patients. The levels of serum CA15-3 in 23 primary breast cancer patients did not correlate to the percentage cytoplasmic reactivity of MAb DF3 with the carcinoma cells in tissue specimens from each respective patient. In 17 patients who subsequently developed metastatic breast cancer, however, the serum CA15-3 concentrations generally correlated well to the cytoplasmic reactivity of MAb DF3 with the carcinoma cells in specimens obtained at initial biopsy or mastectomy. Elevated levels of serum CA15-3 were seen in metastatic breast cancer patients when the carcinoma cells in their primary specimens expressed enhanced levels of cytoplasmic DF3 antigen. The results of this study suggest that the immunohistochemical demonstration of DF3 antigen in tissue specimens, together with the periodical measurement of circulating CA15-3 antigen, may be important for monitoring the clinical course of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646903     DOI: 10.1007/bf02470899

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  18 in total

1.  Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen.

Authors:  D C Tormey; T P Waalkes; J J Snyder; R M Simon
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

2.  Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

Authors:  D F Hayes; V R Zurawski; D W Kufe
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

3.  CA 15.3: early results of a new breast cancer marker.

Authors:  R Colomer; L A Sole; M Navarro; G Encabo; A Ruibal; L Salvador
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

4.  Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas.

Authors:  H Sekine; T Ohno; D W Kufe
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

5.  Serum sialyltransferase and 5'-nucleotidase as reliable biomarkers in women with breast cancer.

Authors:  T L Dao; C Ip; J Patel
Journal:  J Natl Cancer Inst       Date:  1980-09       Impact factor: 13.506

6.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.

Authors:  C Tondini; D F Hayes; R Gelman; I C Henderson; D W Kufe
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

7.  Possible cancerous change of intraductal papillomas of the breast. A 3-D reconstruction study of 25 cases.

Authors:  N Ohuchi; R Abe; M Kasai
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

8.  Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.

Authors:  J Lundy; A Thor; R Maenza; J Schlom; F Forouhar; M Testa; D Kufe
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

9.  MAM-6 antigen, a new serum marker for breast cancer monitoring.

Authors:  J Hilkens; V Kroezen; J M Bonfrer; M De Jong-Bakker; P F Bruning
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

10.  Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors.

Authors:  J Hilkens; F Buijs; J Hilgers; P Hageman; J Calafat; A Sonnenberg; M van der Valk
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

View more
  3 in total

1.  A Case of Breast Cancer Metastatic to the Pituitary Gland.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line.

Authors:  N Ohuchi; Y Harada; T Masuko; S Matano; S Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

3.  The value of serum tumour markers in the prediction of aetiology and follow up of patients with pericardial effusion.

Authors:  U Bildirici; U Celikyurt; E Acar; O Bulut; T Sahin; G Kozdag; D Ural
Journal:  Cardiovasc J Afr       Date:  2012-04       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.